相似文献
1
Plasma binding of disopyramide.
Br J Clin Pharmacol. 1980 Jun;9(6):614-8. doi: 10.1111/j.1365-2125.1980.tb01090.x.
2
Role of concentration-dependent plasma protein binding in disopyramide disposition.
J Pharmacokinet Biopharm. 1979 Feb;7(1):29-46. doi: 10.1007/BF01059439.
3
Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
J Pharmacol Exp Ther. 1981 Dec;219(3):741-7.
4
The influence of blood collection technique on serum and plasma protein binding of disopyramide.
Eur J Clin Pharmacol. 1982;22(2):185-9. doi: 10.1007/BF00542466.
5
The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
J Int Med Res. 1976;4(1 Suppl):49-53.
6
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
Br J Clin Pharmacol. 1983 Apr;15(4):435-41. doi: 10.1111/j.1365-2125.1983.tb01527.x.
7
Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.
J Pharm Sci. 1974 Dec;63(12):1877-9. doi: 10.1002/jps.2600631210.
8
Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
Ther Drug Monit. 1983;5(1):81-6. doi: 10.1097/00007691-198303000-00007.
9
Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.
J Pharm Sci. 1974 Nov;63(11):1684-90. doi: 10.1002/jps.2600631103.
10
Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
J Pharmacol Methods. 1982 Jan;7(1):7-14. doi: 10.1016/0160-5402(82)90053-5.
引用本文的文献
1
Therapeutic drug monitoring: antiarrhythmic drugs.
Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x.
2
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x.
3
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
Br J Clin Pharmacol. 1983 Apr;15(4):435-41. doi: 10.1111/j.1365-2125.1983.tb01527.x.
4
Plasma concentration of disopyramide given as capsules and controlled release tablets.
Eur J Clin Pharmacol. 1983;24(2):199-203. doi: 10.1007/BF00613817.
5
Clinical pharmacokinetics of disopyramide.
J Pharmacokinet Biopharm. 1982 Oct;10(5):465-94. doi: 10.1007/BF01059032.
6
Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.
Br J Clin Pharmacol. 1983 Sep;16(3):344-5. doi: 10.1111/j.1365-2125.1983.tb02175.x.
7
Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Br J Clin Pharmacol. 1984 Nov;18(5):779-84. doi: 10.1111/j.1365-2125.1984.tb02542.x.
8
Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
J Pharmacokinet Biopharm. 1984 Dec;12(6):559-73. doi: 10.1007/BF01059552.
9
Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
Br J Clin Pharmacol. 1986 Sep;22(3):281-6. doi: 10.1111/j.1365-2125.1986.tb02888.x.
10
Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
Br J Clin Pharmacol. 1987 Aug;24(2):199-206. doi: 10.1111/j.1365-2125.1987.tb03162.x.
本文引用的文献
1
Sequential changes of plasma proteins after myocardial infarction.
Scand J Clin Lab Invest Suppl. 1972;124:117-26. doi: 10.3109/00365517209102759.
2
Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.
J Pharm Sci. 1974 Dec;63(12):1877-9. doi: 10.1002/jps.2600631210.
3
Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.
J Pharm Sci. 1974 Nov;63(11):1684-90. doi: 10.1002/jps.2600631103.
4
Equilibrium dialysis and circular dichroic analysis of the novobiocin-human serum albumin complex.
Arch Biochem Biophys. 1975 Mar;167(1):91-8. doi: 10.1016/0003-9861(75)90444-0.
5
The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
J Int Med Res. 1976;4(1 Suppl):49-53.
6
Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.
J Pharmacokinet Biopharm. 1976 Jun;4(3):199-230. doi: 10.1007/BF01063614.
7
Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):539-44.
8
Role of concentration-dependent plasma protein binding in disopyramide disposition.
J Pharmacokinet Biopharm. 1979 Feb;7(1):29-46. doi: 10.1007/BF01059439.
9
Disopyramide kinetics in patients with acute myocardial infarction.
Clin Pharmacol Ther. 1979 Jul;26(1):1-7. doi: 10.1002/cpt19792611.
10
Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
Drugs. 1978 May;15(5):331-68.
Zotero 插件